Rewriting Fat Itself: Hoth Therapeutics May Be Targeting the Root of Metabolic Disease [TheStreet.com]
Hoth Therapeutics, Inc. (HOTH)
Company Research
Source: TheStreet.com
competitive, and lucrative, arenas in biotech with data that suggests a fundamentally different approach to treating metabolic disease. Rather than simply helping patients lose weight, the company's latest HT-VA study indicates it may be able to reprogram how the body creates and burns fat at the genetic level The study, conducted under a Cooperative Research and Development Agreement with the U.S. Department of Veterans Affairs and Emory University, focused on Glial Cell-Derived Neurotrophic Factor (GDNF) in a preclinical model of metabolic-associated fatty liver disease (MAFLD). What emerged is a narrative that challenges the current dominance of weight-loss-first therapies, particularly GLP-1 drugs like semaglutide. In key gene expression markers tied to liver fat regulation, GDNF not only showed statistically significant improvements and outperformed semaglutide At the center of the findings are two critical genetic switches. GDNF significantly reduced Srebf1, a gene responsib
Show less
Read more
Impact Snapshot
Event Time:
HOTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOTH alerts
High impacting Hoth Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOTH
News
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming SemaglutidePR Newswire
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide [Yahoo! Finance]Yahoo! Finance
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide [TheStreet.com]TheStreet.com
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming SemaglutidePR Newswire
- Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct OfferingPR Newswire
HOTH
Sec Filings
- 4/16/26 - Form 8-K
- 4/16/26 - Form 424B5
- 4/2/26 - Form 8-K
- HOTH's page on the SEC website